biostudies-literatureUddin MJNational Cancer InstituteNCI NIH HHSV Foundation for Cancer ResearchNIH HHS9251-9261https://www.ebi.ac.uk/biostudies/studies/S-EPMC6545551biostudies-literatureUnknown4(5)In vivo targeting and visualization of cyclooxygenase-1 (COX-1) using multimodal positron emission tomography/computed tomography imaging represents a unique opportunity for early detection and/or therapeutic evaluation of ovarian cancer because overexpression of COX-1 has been characterized as a pathologic hallmark of the initiation and progression of this disease. The furanone core is a common building block of many synthetic and natural products that exhibit a wide range of biological activities. We hypothesize that furanone-based COX-1 inhibitors can be designed as imaging agents for the early detection, delineation of tumor margin, and evaluation of treatment response of ovarian cancer. We report the discovery of 3-(4-fluorophenyl)-5,5-dimethyl-4-(<i>p</i>-tolyl)furan-2(5<i>H</i>)-oneACS omegaDiscovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer.PMC6545551CA136465P01 CA077839CA182850-01A1R01 CA089450P50 CA128323CA89450CA128323-4, -5R15 CA182850U54 CA136465S10 OD017997Marnett LJMalerba PKingsley PJJashim EUddin MJUddin MIDaniel CKManning HCTantawy MNNickels MLWilson AJGhebreselasie KKhabele DCrews BCfalseDiscovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer.In vivo targeting and visualization of cyclooxygenase-1 (COX-1) using multimodal positron emission tomography/computed tomography imaging represents a unique opportunity for early detection and/or therapeutic evaluation of ovarian cancer because overexpression of COX-1 has been characterized as a pathologic hallmark of the initiation and progression of this disease. The furanone core is a common building block of many synthetic and natural products that exhibit a wide range of biological activities. We hypothesize that furanone-based COX-1 inhibitors can be designed as imaging agents for the early detection, delineation of tumor margin, and evaluation of treatment response of ovarian cancer. We report the discovery of 3-(4-fluorophenyl)-5,5-dimethyl-4-(<i>p</i>-tolyl)furan-2(5<i>H</i>)-one2019-01-01T00:00:00Z2019 May2025-04-18T14:12:36.379Z2019-07-24T07:08:12ZS-EPMC65455513117204610.1021/acsomega.9b01093